专家问答：生成式人工智慧如何让 GVD 製作更简单

随着越来越多的製药公司考虑使用生成式人工智慧来增强全球价值檔案 (GVD) 的创建，简化工作流程、整合证据和优化上市策略的潜力正变得越来越明显。

为了了解人工智慧如何改变这个过程，FirstWord 采访了 S3 Connected Health 的咨询服务专案经理 Hany Mina。

报告的内容

• 生成式 AI 目前如何用于建立 GVD？
• 与传统方法相比，生成式 AI 为 GVD 创作过程带来了哪些独特优势？
• 生成式 AI 将如何改变从事 GVD 的医学写作和市场进入团队的工作流程？
• 生成式 AI 在为 GVD 创建核心内容（例如价值叙述、临床摘要和经济模型资料）方面有多有效？
• 生成式 AI 能否协助针对特定市场或受众客製化 GVD？
• 在 GVD 开发中使用生成式 AI 时，您节省了哪些时间和成本？
• 确保资料准确性在 GVD 中非常重要，但需要采取哪些措施来验证生成式 AI 的输出？
• 如何使用生成式人工智慧为不同的利害关係人客製化 GVD 的内容？
• 我们如何控制生成式 AI 的资料输入，以便仅连接已识别的资料来源并使用正确的资料来支援 GVD 的生成？
• 如何优化生成式人工智慧以满足 GVD 严格的监管标准，尤其是在受到严格监管的市场中？
• 生成式人工智慧的创新预计将在未来五年对 GVD 创作产生最大影响
• 考虑到生成式 AI 在创建 GVD 方面的整体情况，您是否建议添加其他模组或解决方案？
• 对于刚开始考虑使用生成式 AI 进行 GVD 开发的公司，您会给予什么建议？

As pharmas increasingly explore genAI to enhance global value dossier (GVD) creation, its potential to streamline workflows, synthesise evidence and optimise market access strategies is becoming more apparent.

To understand how AI is transforming this process, FirstWord spoke with Hany Mina, consulting services program manager at S3 Connected Health.

Key Questions Answered:

• How is genAI currently being used in GVD creation?
• What unique advantages does genAI bring to the process of creating GVDs compared with traditional approaches?
• Do you see genAI transforming workflows within the medical writing and market access teams responsible for GVDs?
• How effective is genAI in generating core GVD content, such as value narratives, clinical summaries and economic modelling data?
• Can genAI assist in tailoring GVDs for specific markets or audiences?
• What kind of time and cost-savings have you observed when using genAI for GVD development?
• Ensuring data accuracy is critical in a GVD. What measures are necessary to validate outputs from genAI?
• How can genAI be leveraged to tailor GVD content for different stakeholders?
• How can we control the data input to genAI to ensure only identified data sources are connected and correct data are consumed to support GVD generation?
• How can genAI be optimised to meet stringent regulatory standards in GVDs, especially in highly regulated markets?
• What innovations in genAI do you foresee having the biggest impact on GVD creation in the next five years?
• Thinking of the big picture for genAI in GVD creation, are there other modules or solutions you suggest adding?
• What advice would you give to companies just beginning to explore genAI for GVD development?

Methodology

Dossier reports are developed from independent and concise analysis derived from original industry surveys and in-depth interviews with industry thought leaders. Reports analyse in detail significant developments and market trends that pharma executives need to understand if they are to manage the opportunities and challenges that lie ahead. The focus of each report is defined by a review of the secondary literature and any knowledge gaps identified. Based on this initial research, an evidence-based and expert-informed discussion guide is developed to ensure the research answers the most critical questions. Additionally, robust screening criteria are established to ensure that those interviewed are qualified in terms of their experience, knowledge and stature to speak on the topic.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.